CureVac Converts To Modified mRNA And Stock Soars
New CEO Incoming
Executive Summary
CureVac, formerly a cheerleader of the unmodified mRNA approach, is embracing the modified version for its vaccine portfolio, a move that has gone down well with the investment community.
You may also be interested in...
GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease
COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.
BIO Notebook: GSK’s Walmsley On M&A, Merck On How Falling Valuations Are Affecting Deals
On the first day of the BIO International Convention, our reporters hear from industry leaders about tough financing, when to go public, and why ‘there shouldn't be 700 listed biotechs in the US.’
BIO Notebook: GSK’s Walmsley On M&A, Merck On How Falling Valuations Are Affecting Deals
On the first day of the BIO International Convention, our reporters hear from industry leaders about tough financing, when to go public, and why ‘there shouldn't be 700 listed biotechs in the US.’